Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eloxx Pharmaceuticals Inc (ELOX)

Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,546
  • Shares Outstanding, K 3,143
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,070 K
  • 60-Month Beta 2.75
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ELOX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.07
  • Most Recent Earnings $-1.31 on 11/13/23
  • Latest Earnings Date 05/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -2.88
  • Growth Rate Est. (year over year) +34,787.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7875 +2.86%
on 04/23/24
1.1000 -26.36%
on 04/12/24
-0.1010 (-11.09%)
since 03/22/24
3-Month
0.7401 +9.44%
on 02/15/24
1.3900 -41.73%
on 03/13/24
-0.0614 (-7.05%)
since 01/24/24
52-Week
0.4000 +102.50%
on 12/14/23
10.9000 -92.57%
on 05/15/23
-5.9800 (-88.07%)
since 04/24/23

Most Recent Stories

More News
This Small Cap Stock Surged Over 100%

Shares of Eloxx Pharmaceuticals (NASDAQ: ELOX) rocketed almost 100% on Tuesday after receiving an increased price target from Oppenheimer.

ELOX : 0.8100 (-1.82%)
Are Medical Stocks Lagging Elevation Oncology (ELEV) This Year?

Here is how Elevation Oncology, Inc. (ELEV) and Senesco Technologies Inc. (ELOX) have performed compared to their sector so far this year.

ELEV : 3.58 (-7.73%)
ELOX : 0.8100 (-1.82%)
Senesco Technologies Inc. (ELOX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Senesco Technologies Inc. (ELOX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement...

ELOX : 0.8100 (-1.82%)
Biotech Stock Roundup: GILD, BMY's Regulatory News, BLUE's Therapy Approval & More

Regulatory and pipeline updates from BMY and GILD are the key highlights from the biotech sector during the past week.

ALNY : 144.81 (+0.70%)
BMY : 44.66 (-8.60%)
GILD : 65.34 (-2.59%)
BLUE : 0.8997 (-2.51%)
ELOX : 0.8100 (-1.82%)
Eloxx (ELOX) Down After Cystic Fibrosis Study Fails to Meet Goal

Eloxx Pharmaceuticals' (ELOX) phase II combination study evaluating pipeline candidate ELX-02 in cystic fibrosis fails to achieve statistical significance in efficacy endpoints.

VRTX : 399.03 (-0.43%)
KMDA : 5.14 (-0.77%)
ELOX : 0.8100 (-1.82%)
MORF : 27.76 (+0.25%)
Eloxx Pharmaceuticals Announces Changes to Board of Directors

Lindsay Androski, JD, MBA brings significant experience growing biotech companies through her roles as an executive at Roivant Social Ventures Gadi...

ELOX : 0.8100 (-1.82%)
Eloxx Pharmaceuticals Reports First Quarter 2022 Financial and Operating Results and Provides Business Update

Cystic Fibrosis Foundation (CF Foundation) awarded up to $15.9 million for the ongoing ELX-02 clinical program Topline data from cystic fibrosis (CF)...

ELOX : 0.8100 (-1.82%)
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update

Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor by the end of the first half of 2022 ...

ELOX : 0.8100 (-1.82%)
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical...

ELOX : 0.8100 (-1.82%)
Eloxx Pharmaceuticals Announces Therapeutic Development Award from Cystic Fibrosis Foundation

Cystic Fibrosis Foundation (CF Foundation) to provide an award of up to $15.9 million for the ongoing ELX-02 clinical program Expect topline data from...

ELOX : 0.8100 (-1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed...

See More

Key Turning Points

3rd Resistance Point 0.8733
2nd Resistance Point 0.8567
1st Resistance Point 0.8333
Last Price 0.8100
1st Support Level 0.7933
2nd Support Level 0.7767
3rd Support Level 0.7533

See More

52-Week High 10.9000
Fibonacci 61.8% 6.8890
Fibonacci 50% 5.6500
Fibonacci 38.2% 4.4110
Last Price 0.8100
52-Week Low 0.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar